News

Under the terms of the agreement, Wyeth made an up-front equity investment in Advanced Life Sciences through the purchase of common stock representing approximately 4.9% of the company’s

The 10mg/ml strength joins Bioniche’s current offering of Ketamine in 50mg/ml and 100mg/ml strengths and completes its full product line offering. Bioniche plans to launch the 10mg/ml strength

CodeLink activated slides use SurModics’s PhotoLink technology to create a three-dimensional matrix that allows the attachment of biomolecules to form microarrays. Bruce Barclay, president and CEO of SurModics,

If approved, Pharmaxis will be authorized to market Bronchitol in Australia for the treatment of bronchiectasis. The application is based on a multicentre Phase III clinical trial involving

BioChemics (BCI) has developed a novel, transdermal drug delivery system called Vale (vaso-active lipid encapsulated), that allows a wide variety of actives to be delivered into the skin.

This use of once-daily Reyataz boosted with ritonavir (Reyataz/r) in HIV-1 infected treatment-naive adult patients is based on 48-week results from the Castle study, which demonstrated similar antiviral

In addition, the efficacy as measured by the mean insulin-like growth factor 1 (IGF-1) and growth hormone (GH) plasma levels is maintained at the same level throughout the

ColoSure is said to be the first clinical test available that looks for a DNA change in the vimentin gene, shown to be important to immunity and other

Mr Howes brings more than 20 years of senior-level pharmaceutical experience to Inotek, most recently serving as president of the Americas Region for Bausch & Lomb where he